Anuh Pharma revenue up 16%, but profit slips 13% in FY26
Top-line growth couldn't protect margins: PAT fell to ₹41.05 cr despite a ₹771.66 cr top line.
— 3 earlier stories on Anuh Pharma Ltd. →What's new
- Revenue grew 16.6% to ₹771.66 cr in FY26.
- Profit after tax dropped 13.3% to ₹41.05 cr.
- Board recommended a ₹1.50/share dividend, flat YoY.
Why it matters
This divergence between top-line growth and bottom-line pressure signals margin compression. With revenue up but profit down, the company's cost structure or pricing power is under strain. Investors should look past the growth headline to earnings quality.
What we're watching
- Margin trajectory in Q1 FY27 results.
- Management's commentary on cost pressures or one-off items.
- Any guidance on volume vs pricing mix.
The full read
Anuh Pharma reported a 16.6% revenue jump to ₹771.66 cr for FY26, but profit after tax fell 13.3% to ₹41.05 cr — a rare divergence that shifts the narrative from growth to margin health. The ₹1.50/share dividend recommendation matches the prior year. Other board items — reappointments, auditor appointments, promoter reclassification — are procedural. The key takeaway is that rising top line didn't convert to profit, raising questions on input costs or pricing. The next quarter will show whether this is a blip or a trend.